Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines
<p>Abstract</p> <p>Background</p> <p>STAT3 [1] has been shown to be dysregulated in nearly every major cancer, including osteosarcoma (OS). Constitutive activation of STAT3, via aberrant phosphorylation, leads to proliferation, cell survival and resistance to apoptosis....
Main Authors: | Couto Jason I, Bear Misty D, Lin Jiayuh, Pennel Michael, Kulp Samuel K, Kisseberth William C, London Cheryl A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | BMC Veterinary Research |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1746-6148/8/244 |
Similar Items
-
Biologic Activity of the Novel Small Molecule STAT3 Inhibitor Against Canine Osteosarcoma Cell Lines
by: Couto, Jason
Published: (2013) -
Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
by: William C. Kisseberth, et al.
Published: (2021-06-01) -
Genome-wide Analysis of Copy Number Aberrations in Canine Osteosarcoma
by: Liu, Jonathan
Published: (2011) -
Characterization of STAT3 Activation in Osteosarcoma
by: Fossey, Stacey L.
Published: (2010) -
MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future?
by: Olivia Gourbault, et al.
Published: (2020-09-01)